Whereas Sabinsa’s original ForsLean patents defined its use and composition in promotion of lean body mass, reduction of adipose tissue (fat), and weight loss, the new patents outline a molecular mechanism: how Forskolin actually aids in fat conversion into heat, a novel concept called energy balance. Humans possess white fat tissue (WAT) and brown fat tissue (BAT). While WAT stores energy in the form of triglycerides, BAT dissipate energy in the form of heat. Forskolin, by recruiting secretory factors like bone morphogenic factors (BMPs), aids in the conversion of WAT to BAT, which is crucial for fat utilization and effective energy utilization (balance). This is a preferred preventive measure from obesity and metabolic imbalance.
“The granting of these patents further illustrates our steadfast commitment to furthering science and bringing new understanding to the benefits of Forskolin to humankind,” said Sabinsa founder Dr. Muhammed Majeed.
Sabinsa was the first to introduce Coleus forskolii extract to the dietary supplement marketplace, and the first to recognize its weight management potential. The ForsLean branded ingredient won the Nutracon Best New Product Award in 2001, and in 2004 it was recognized by Thomas Alva Edison Patent Awards.
For more information, please visit Sabinsa at SupplySide East booth #D101.